Biotechnology / biotech/low-cost-dna-sequencing
Low-cost DNA sequencing
Reading the sequence of a human genome, at about 30-fold coverage, for a cost low enough that sequencing is a routine step in research, screening and diagnosis.
Scope
In: instruments, chemistry and workflows that read DNA, and the cost per human genome. Out: the interpretation of the sequence, and DNA writing (biotech/low-cost-dna-synthesis).
- Readiness
- not assessed
- Serves
- Good health and well-being, Industry, innovation and infrastructure
- Last reviewed
- 2026-10-04
- Curators
- none yet: volunteer
Metrics
Gaps
Reagent price is not the cost of a genome
The per-gigabase price quoted by a platform developer leaves out what NHGRI counts as production cost: labor, instruments amortized over three years, informatics and data submission. The atlas has no independent figure for the full cost of a 30-fold human genome today, so the current value is a derived, developer-reported number.
Dependencies
Requires
Nothing recorded.
Required by
- Multi-cancer early detection Methylation and fragment-based tests read cell-free DNA by sequencing, so test price follows sequencing price.
Holds open
- Low sensitivity for stage I cancersMulti-cancer early detection
Arrows point from a technology to what it requires. Select a node to open it.